# Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas

> **NCT01788189** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Essen** · enrollment: 37 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01788189
- **Lead sponsor:** University Hospital, Essen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-02-20
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788189, "Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01788189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*